Dictatorship in the drug industry
The Government has failed to respond adequately to the report last year of the House of Commons Health Select Committee inquiry into the influence of the pharmaceutical industry, according to Joe Collier of the University of London, who is an adviser to the committee.
Writing in The Lancet for 14 January, Dr Collier says that the inquiry, which
began in June 2004, revealed much evidence about the industry’s influence
on how health professionals can determine issues of public health. Briefly, he
concludes that this influence is “enormous and out of control”. It
is directed at patients, health departments, regulators, managers, researchers,
medical charities, academics, the media of mass communication, carers, schoolchildren
and politicians. Moreover, large multinational drug companies design, sponsor,
orchestrate and control the publication of key drug trials, and they promote
the medicines we take and virtually how they are prescribed.
Among the committee’s recommendations was a call for a public inquiry into
the workings of the Medicines and Healthcare Regulatory Agency, which committee
members considered was not competent to undertake its duties as a guardian of
public health. However, the Government declined such an inquiry in favour of
a four-yearly review based on expert knowledge.
In response to other recommendations, health agencies are to examine drug promotional
material to improve efficiency and damp the explosive marketing that accompanies
product launches. The circumstances in which UK licensed medicines are withdrawn
are also to be published. A recommendation that official sponsorship of the drug
industry should be moved from the Department of Health to the Department of Trade
and Industry was rejected, although many MPs see the current situation as involving
a conflict of interest.
The Government also rejected a proposal that drug launches should be delayed
until full clinical trials have appeared on a public register. Problems with
EU legislation were cited but, says Dr Collier, the real reason is that the move
would interfere with drug company sales.
Dr Collier concludes that the welfare of patients will remain vulnerable so long
as the influence of big business interests continues to dominate health policies
and practice.
Back to Top
|